Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044121 | 0.90 | MDM4 (0.44) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL14286245 | 0.90 | MDM4 (0.44) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL2760583 | 0.90 | MDM4 (0.44) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL13413133 | 0.88 | MDM4 (0.40) | CASP3MDM4TP53KMT2A | |
| SCHEMBL800110 | 0.81 | CASP3 (0.56) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL30089356 | 0.81 | CASP3 (0.56) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL10628626 | 0.81 | CASP3 (0.52) | CASP3MDM4TP53PTPN1KMT2A | |
| SCHEMBL29398190 | 0.79 | MDM4 (0.48) | CASP3MDM4TP53KMT2A | |
| SCHEMBL29117234 | 0.79 | MDM4 (0.48) | CASP3MDM4TP53KMT2A | |
| SCHEMBL29979418 | 0.79 | MDM4 (0.48) | CASP3MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809498-B2 | Pepstatin A derivatives | FREIE UNIVERSITAET BERLIN (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8809498-B2 | Pepstatin A derivatives | FREIE UNIVERSITAET BERLIN (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8809498-B2 | Pepstatin A derivatives | FREIE UNIVERSITAET BERLIN (DE) | 2014-08-19 | — | — | US | disclosed |
| US-20120016103-A1 | PEPSTATIN A DERIVATIVES | FREIE UNIVERSITAET BERLIN | 2012-01-19 | — | — | US | disclosed |
| US-20120016103-A1 | PEPSTATIN A DERIVATIVES | FREIE UNIVERSITAET BERLIN | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016103-A1 | PEPSTATIN A DERIVATIVES | PEPD, ANPEP, VIP | CASP3 2509/4885MDM4 3026/4885TP53 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.